Publication & Citation Trends
Most Cited Works
Publications
12 total
Emicizumab in people with moderate or mild haemophilia A (HAVEN 6): a multicentre, open-label, single-arm, phase 3 study PDF
Cited by 82
OpenAlex
Emicizumab use in females with moderate or mild hemophilia A without factor VIII inhibitors who warrant prophylaxis PDF
Cited by 4
OpenAlex
Idasanutlin Plus Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia: Results of the MIRROS Trial PDF
Cited by 68
OpenAlex
Emicizumab Prophylaxis in Persons with Mild or Moderate Hemophilia A: Results from the Interim Analysis of the HAVEN 6 Study
Cited by 13
OpenAlex
MIRROS: A Randomized, Placebo-Controlled, Phase III Trial of Cytarabine ± Idasanutlin in Relapsed or Refractory Acute Myeloid Leukemia PDF
Cited by 73
OpenAlex
Contribution of Idasanutlin Exposure to Safety, Pharmacodynamics and Clinical Response of Patients with Acute Myeloid Leukemia Treated with Idasanutlin + Cytarabine in Phase I and III Studies
Cited by 3
OpenAlex
Patient-reported outcomes (PROs) from MARIANNE: A phase III study of trastuzumab emtansine (T-DM1) +/- pertuzumab (P) vs trastuzumab + taxane (HT) for HER2-positive advanced breast cancer.
Cited by 1
OpenAlex
Targeting of cancer stem cell marker EpCAM by bispecific antibody EpCAMxCD3 inhibits pancreatic carcinoma PDF
Cited by 44
OpenAlex
Research Topics
Acute Myeloid Leukemia Research
(3)
Cancer Cells and Metastasis
(3)
Acute Lymphoblastic Leukemia research
(3)
Hemophilia Treatment and Research
(3)
Mesenchymal stem cell research
(2)
Frequent Co-Authors
Affiliations
Roche (Switzerland)
German Cancer Research Center
Heidelberg University